SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olsson Anders G.)
 

Sökning: WFRF:(Olsson Anders G.) > (2020-2022) > Association of high...

Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial

Salahuddin, Taufiq (författare)
VA Med Ctr, CO 80045 USA; Univ Colorado, CO USA
Kittelson, John (författare)
VA Med Ctr, CO 80045 USA
Tardif, Jean-Claude (författare)
Univ Montreal, Canada
visa fler...
Shah, Prediman K. (författare)
Cedars Sinai Med Ctr, CA 90048 USA
Olsson, Anders, 1940- (författare)
Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten
Nicholls, Stephen J. (författare)
Monash Univ, Australia
Leitersdorf, Eran (författare)
Hadassah Hebrew Univ, Israel
Leiter, Lawrence A. (författare)
Univ Toronto, Canada
Kallend, David (författare)
Medicines Co, Switzerland
Black, Donald M. (författare)
Dalcor Pharmaceut, Switzerland
Barter, Philip J. (författare)
Univ New South Wales, Australia
Ballantyne, Christie M. (författare)
Baylor Coll Med, TX 77030 USA
Schwartz, Gregory G. (författare)
VA Med Ctr, CO 80045 USA; Univ Colorado, CO USA
visa färre...
 (creator_code:org_t)
MOSBY-ELSEVIER, 2020
2020
Engelska.
Ingår i: American Heart Journal. - : MOSBY-ELSEVIER. - 0002-8703 .- 1097-6744. ; 221, s. 60-66
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with established coronary heart disease. HDL particle concentration (HDLP) has been proposed as a better predictor of risk. We investigated whether HDLP is associated with risk of MACE after acute coronary syndrome (ACS). Methods The dal-Outcomes trial compared the CETP inhibitor dalcetrapib with placebo in patients with recent ACS. In a nested case-cohort analysis, total, large, medium, and small HDLPs were measured by nuclear magnetic resonance spectroscopy at baseline (4-12 weeks after ACS) in 476 cases with MACE and 902 controls. Hazard ratios (HRs; case-control) for 1-SD increment of HDLP or HDL-C at baseline were calculated with and without adjustment for demographic, clinical, laboratory, and treatment variables. Similarly, HRs for MACE were calculated for changes in HDLP or HDL-C from baseline to month 3 of assigned treatment. Results Over median follow-up of 28 months, the risk of MACE was not associated with baseline HDLP (adjusted HR = 0.98, 95% CI = 0.84-1.15, P =.81), any HDLP subclass, or HDL-C. Dalcetrapib increased HDL-C and total, medium, and large HDLP and decreased small HDLP but had no effect on MACE compared with placebo. There were no association of risk of MACE with change in HDLP or HDL-C and no interaction with assigned study treatment. Conclusions Neither baseline HDLP nor the change in HDLP on treatment with dalcetrapib or placebo was associated with risk of MACE after ACS.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy